Bloodshot: Valiant Comics Character Slated For Live Action Feature

SuperHeroStuff - Shop Now!

Valiant Comics Bloodshot will grace the big screen as it was aquired by Sony to develop Bloodshot as a feature film.

This is a first for the company whose properties also include XO: Manowar, Magnus:Robot Fighter, Harbinger, Rai, Eternal Warrior and many other others. As reported, The deal was $450,000 against $1 million and Jeff Wadlow will write the script. Neal Moritz will produce through his Original Film Banner along with Jason Kothari and Dinesh Shamdasani for Valiant Entertainment.

Besides Marvel and DC being the books I was introduced to as a kid, Valiant is still one of my favorite comic properties. I’m wondering though, will the book stay true to it’s violent roots? Will this serve as an introduction for the rest of the Valiant characters? Only time will tell.

Bloodshot originated in Valiant Comics form in 1992 and appeared in over 70 issues, becoming the cornerstone of the Valiant Universe. The protagonist is Angelo Mortalli, a ruthless killer for the mob who is set up by the family and framed for a murder. He instead goes into Witness Protection, but is betrayed by an FBI agent guarding him, kidnapped and forcibly subjected to an experimental program in which his body is injected with microscopic computers called nanites. They erase his brain and rebuild it and his body to be a weapon with superhuman strength and healing powers. Bloodshot escapes his makers, and though he isn’t his old self, he tries to figure out who he was. Things get bad for everybody who betrayed him. The project had been rumored as a possible directing vehicle for Matthew Vaughn, but he isn’t part of this equation. Wadlow is repped by WME.

Enhanced by Zemanta


This article was submitted by one of ComicBookTherapy’s contributors. Every contributor must agree and abide by ComicBookTherapy’s Site User Agreement. is protected from liability under “OCILLA” (Online Copyright Infringement Liablity Limitation Act) and will actively enforce said provisions. If you represent an individual or company and feel as though this article has infringed on any of our terms or any existing copyrights, please contact us for a speedy removal.


Source : Deadline